Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.42 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.42 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911151 | 0.85 | CMA1 (0.43) | MAOBPSMB5PSMB8NQO1PTGES | |
| SCHEMBL5447303 | 0.82 | ALDH1A1 (0.50) | PTGS2NPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL12911144 | 0.73 | CMA1 (0.40) | MAOBPSMB5PSMB8PTGESPTGS2 | |
| SCHEMBL29076119 | 0.73 | MAOB (0.48) | MAOBPSMB5NQO1PTGESPTGS2 | |
| SCHEMBL29076121 | 0.73 | MAOB (0.48) | MAOBPSMB5NQO1PTGESPTGS2 | |
| SCHEMBL12987640 | 0.73 | MAOB (0.56) | MAOBPSMB5PSMB8MAPTALDH1A1 | |
| SCHEMBL12911148 | 0.73 | CMA1 (0.44) | MAOBPSMB5PSMB8NPC1MAPT | |
| SCHEMBL16376975 | 0.72 | ALDH1A1 (0.49) | MAPTALDH1A1L3MBTL1 | |
| SCHEMBL27598322 | 0.72 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1 | |
| SCHEMBL23116703 | 0.72 | MAOB (0.55) | MAOBPSMB5PSMB8MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | MAOB 1769/4885PSMB5 2396/4885PSMB8 1197/4885 |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | MAOB 4254/4885PSMB5 2390/4885PSMB8 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.